Please assess the completion status of the following clinical trial:

Trial Title: Cardioprotective Effects of GLP-1 and Their Mechanisms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18~* Able to give informed consent~* Elective percutaneous intervention for a single vessel coronary stenosis~* Normal left ventricular function~Exclusion Criteria:~* Severe Co-morbidity~* Type 2 Diabetes Mellitus~* Nicorandil, Sulphonylureas, DPP4 inhibitors, GLP-1 agonists or Insulin use~* Women of child bearing age~* Myocardial infarction in previous three months~* Previous coronary artery bypass grafts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLP-1 (7-36) amide and Glibenclamide (Type: EXPERIMENTAL): Patients will receive 5mg Glibenclamide orally prior to PCI and infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min during PCI
- Glibenclamide alone (Type: EXPERIMENTAL): Glibenclamide 5 mg orally prior to PCI
- GLP-1 (7-36) amide (Type: ACTIVE_COMPARATOR): GLP-1 (7-36) amide
- Saline control (Type: NO_INTERVENTION): 0.9% saline only (no treatment with GLP-1 (7-36) amide or glibenclamide)

Based on this trial design, predict the completion outcome and termination type (if applicable).